Immutep Limited

NASDAQ:IMMP

Biotechnology

Healthcare
$0.37 +0.64%

+$0.00 today

Market cap
$55.01M
Beta
2.24
P/E (TTM)
-0.9
EPS (TTM)
-$0.06
52W Low $0.29High $3.53

Volume 3.10M

Average 13.46M

Returns on capital

Immutep Limited management

Start with the returns management earns on the capital it controls, then review the people, their trades, and growth quality.

Return Metrics

ROE, ROIC & ROA over time

Management
Older years hidden. Sign in to unlock

ROE

-42.8%

avg -59.6%

ROIC

-86.9%

avg -54.9%

ROA

-39.1%

avg -48.0%

Analysis

ROA is currently the strongest return metric at -39.1% versus its period average of -48.0%. 0 of 3 return metrics are above their quality threshold, which helps indicate how efficiently the company turns capital and assets into profit.

Leadership

Who runs the company?

Review the executive team, tenure, compensation, and ownership.

Management

Key executives, compensation & ownership

NameTitleCompensationAgeShares OwnedOwnership %

Marc Voigt

Chief Executive Officer, MD, Chief Financial Officer, Chief Business Officer & Executive DirectorAUD 610.1K530<0.01%

Frederic Triebel

Chief Scientific Officer & Executive DirectorAUD 504.27K71——

Stephan Winckels

Chief Medical OfficerAUD 478.17K———

Deanne Miller

Chief Operating Officer, General Counsel & Joint Company SecretaryAUD 371.94K49——

Christian Mueller

Chief Development OfficerAUD 279.68K—0<0.01%

Indira Naidu

Joint Company Secretary————

Compensation is shown in the reported currency; data updated Aug 29, 2026.

Ownership uses each executive's latest SEC Form 4 holding only when the full name maps to one reporting CIK; latest matched holding Dec 1, 2028.

Insider trading

Are insiders buying or selling?

Follow recent insider purchases and sales reported on Form 4.

Insider Trading

SEC Form 4 transactions — last 12 months

No open-market purchases or sales in the last 12 months.

Growth analysis

Is management growing the business?

Compare historical growth with analyst forecasts across revenue, earnings, and cash flow.

Growth Analysis

Historical CAGR & forward analyst estimates

Metric 10yr 5yr3yr Fwd Est.
EPSN/AN/AN/A
N/A1 analysts
RevenueN/AN/A+209.4%
+76.1% (6yr)1 analysts
Net IncomeN/AN/AN/A
N/A1 analysts
EBITN/AN/AN/A
N/A1 analysts

Analysis

Recent growth has been strongest in Revenue at +209.4% over three years. Forward estimates point to Revenue at +76.1% (6yr), giving you a quick check on whether expectations are accelerating or cooling.

Competitors

Who does Immutep Limited compete with?

Open similar companies to compare how their management teams allocate capital.

Questions

Management questions

Common questions about IMMP's management, answered from reported figures.

Who manages IMMP?

Immutep Limited (IMMP) lists 6 active executives. The top listed executive is Frederic Triebel, Chief Scientific Officer & Executive Director.

Are IMMP insiders buying or selling?

Recent insider activity shows net buying of $0.00.